Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 22 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
BRUPHARM PHARMALAB from Mons, company number BE0785641404, closed financial year 2025 with a result of € 10,043 after tax. For that financial year BRUPHARM PHARMALAB recorded revenue of € 175,274 and equity of € -102,855. Compared with financial year 2024, the result moved from € -45,089 to € 10,043. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.
€ -102,855
▲ € 10,043 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 10,043
▲ still € 45,089 loss in 2024
Profit after tax over the fiscal year.
€ 3,496
▲ € 3,419 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -202,855.
People and assets in 2025
€ 47,496
▲ € 38,530 vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 524
▲ € 395 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 37,655
▲ 106% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 58,722 | € 46,657 | € 49,927 | € 175,274 | ▲ 251% |
| Gross margin | € -13,621 | € -39,506 | € 3,105 | € 85,990 | ▲ € 82,885 |
| Profit after taxes | € -55,100 | € -112,709 | € -45,089 | € 10,043 | ▲ € 55,132 |
| Equity | € 44,900 | € -67,809 | € -112,898 | € -102,855 | ▲ € 10,043 |
| Total debts | € 332,537 | € 376,580 | € 356,701 | € 401,286 | ▲ 12% |
| Cash | € 22,659 | € 2,323 | € 77 | € 3,496 | ▲ € 3,419 |
| Retained profit | € -55,100 | € -167,809 | € -212,898 | € -202,855 | ▲ € 10,043 |
| Balance sheet total | € 377,437 | € 308,771 | € 243,802 | € 298,430 | ▲ 22% |
Key figures of BRUPHARM PHARMALAB, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BRUPHARM PHARMALAB?
What happened at BRUPHARM PHARMALAB in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 10,043. filed late Source: NBB ↗
- New establishment in Mons. KBO
- Start of the company according to the CBE. KBO
In short
From € 55,100 loss in 2022 to € 10,043 profit in 2025.
Best year ever: 2025, with € 10,043 profit.
Establishments
Establishment units
Physical locations of this company
Route de Wallonie (G.) 140
7011 Mons
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0785.641.404
- VAT number
- BE 0785.641.404
- Registered office
- Route de Wallonie (G.) 140, 7011 Mons
- Names & denominations
- BRUPHARM PHARMALAB
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 May 2022
- Peppol
- Active · Active since 16 Dec 2025
- Activities · NACE
Vervaardiging van geneesmiddelen
Groothandel in farmaceutische en medische artikelen
Vervaardiging van andere voedingsmiddelen, neg
Groothandel in andere voedingsmiddelen, neg